Perrigo (PRGO)
(Delayed Data from NYSE)
$24.37 USD
+0.12 (0.49%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $24.36 -0.01 (-0.04%) 4:52 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.37 USD
+0.12 (0.49%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $24.36 -0.01 (-0.04%) 4:52 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
Zacks News
Interpreting Perrigo (PRGO) International Revenue Trends
by Zacks Equity Research
Evaluate Perrigo's (PRGO) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
by Zacks Equity Research
Perrigo (PRGO) reports mixed second-quarter 2024 results. It cuts total net sales forecasts primarily due to expected lower distribution in U.S. store brand in second-half 2024.
Compared to Estimates, Perrigo (PRGO) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Perrigo (PRGO) Q2 Earnings Top Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 10.42% and 5.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Green Thumb Industries Inc. (GTBIF) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Green Thumb Industries Inc. (GTBIF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Perrigo (PRGO) Down 15.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Understanding Perrigo (PRGO) Reliance on International Revenue
by Zacks Equity Research
Explore how Perrigo's (PRGO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates
by Zacks Equity Research
Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.
Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
by Kinjel Shah
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
Insights Into Perrigo (PRGO) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations. Stock price drops 10% after this announcement.
Compared to Estimates, Perrigo (PRGO) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ahead of Perrigo (PRGO) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Perrigo (PRGO) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Aurora Cannabis Inc. (ACB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 16.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.
Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Perrigo (PRGO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
by Zacks Equity Research
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.